TP53 and acute myeloid leukemia: These findings support the significant anti-leukemic effect of anti-CCRL2 ADC in TP53-mutated MDS/AML and particularly erythroleukemic samples is likely associated with the prominent overexpression of the target in these subsets and not with their cell intrinsic sensitivity to the released toxin.